BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 26038770)

  • 1. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
    Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
    Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
    Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
    Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice.
    Kim EH; Lee JH; Pascua PN; Song MS; Baek YH; Kwon HI; Park SJ; Lim GJ; Decano A; Chowdhury MY; Seo SK; Song MK; Kim CJ; Choi YK
    Virol J; 2013 Apr; 10():104. PubMed ID: 23551908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
    Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.
    Rosendahl Huber SK; Camps MG; Jacobi RH; Mouthaan J; van Dijken H; van Beek J; Ossendorp F; de Jonge J
    PLoS One; 2015; 10(6):e0127969. PubMed ID: 26046664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice.
    Yang P; Wang W; Gu H; Li Z; Zhang K; Wang Z; Li R; Duan Y; Zhang S; Wang X
    Antiviral Res; 2014 Nov; 111():1-7. PubMed ID: 25173575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.
    Wong G; Qiu X; Ebihara H; Feldmann H; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S435-42. PubMed ID: 26022441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.